文献速递心境障碍精神分裂症与精神病性障碍儿童青少年精神

蛋白质组范围关联研究揭示精神疾病中蛋白质丰度的遗传成分

Proteome-wide Association Study Provides Insights Into the Genetic Component of Protein Abundance in Psychiatric Disorders.
PubMed 文献 · Biol Psychiatry · 2021-07-06

该研究通过整合四种常见精神疾病的全基因组关联数据与两个独立背外侧前额叶皮层脑蛋白质组(n=376和n=152),识别出61个基因的遗传调控蛋白质丰度与精神疾病风险相关。与转录组范围关联研究比较发现18个重叠基因,提示遗传风险变异可能通过调控mRNA表达和蛋白质丰度 confer 风险。研究突出了包括CNNM2和CTNND1在内的精神分裂症和抑郁症高置信度风险蛋白质,为未来药物开发提供潜在靶点。

要点

  • 识别出61个基因的cis调控蛋白质丰度变化与精神疾病风险相关。
  • 18个基因在蛋白质组和转录组水平均与精神疾病显著关联。
  • CNNM2和CTNND1为精神分裂症和抑郁症高置信度风险蛋白质。

核心结论

  • 遗传风险变异可能通过调控mRNA表达和蛋白质丰度影响精神疾病风险。
  • 研究提供了精神疾病蛋白质丰度遗传成分的新见解,并突出高置信度风险蛋白质作为潜在治疗靶点。

研究设计与样本

  • 蛋白质组范围关联研究,整合四种常见精神疾病的全基因组关联数据与两个独立脑蛋白质组(n=376和n=152,背外侧前额叶皮层)。

主要发现

  • 识别61个基因的遗传调控蛋白质丰度与精神疾病风险相关,包括48个精神分裂症基因、12个双相障碍基因、5个抑郁症基因和2个注意缺陷多动障碍基因。
  • 与转录组范围关联研究比较,发现18个重叠基因在蛋白质组和转录组水平均与精神疾病显著关联。

关键数值与推荐

  • 高置信度风险蛋白质包括CNNM2和CTNND1,涉及精神分裂症和抑郁症。

临床怎么用

  • 高置信度风险蛋白质代表未来药物开发的有前景治疗靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Genome-wide association studies have identified multiple risk variants for psychiatric disorders. Nevertheless, how the risk variants confer risk of psychiatric disorders remains largely unknown. METHODS: We performed proteome-wide association studies to identify genes whose cis-regulated protein abundance change in the human brain were associated with psychiatric disorders. RESULTS: By integrating genome-wide associations of four common psychiatric disorders and two independent brain proteomes (n = 376 and n = 152, respectively) from the dorsolateral prefrontal cortex, we identified 61 genes (including 48 genes for schizophrenia, 12 genes for bipolar disorder, 5 genes for depression, and 2 genes for attention-deficit/hyperactivity disorder) whose genetically regulated protein abundance levels were associated with risk of psychiatric disorders. Comparison with transcriptome-wide association studies identified 18 overlapping genes that showed significant associations with psychiatric disorders at both proteome-wide and transcriptome-wide levels, suggesting that genetic risk variants likely confer risk of psychiatric disorders by regulating messenger RNA expression and protein abundance of these genes. CONCLUSIONS: Our study not only provides new insights into the genetic component of protein abundance in psychiatric disorders but also highlights several high-confidence risk proteins (including CNNM2 and CTNND1) for schizophrenia and depression. These high-confidence risk proteins represent promising therapeutic targets for future drug development.

来源:Biol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Liu J, Li X, Luo XJ, et al. Proteome-wide Association Study Provides Insights Into the Genetic Component of Protein Abundance in Psychiatric Disorders. Biol Psychiatry. 2021. PMID: 34454697. doi:10.1016/j.biopsych.2021.06.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。